NuVasive Receives a Buy from Barclays

By Ryan Adsit

In a report released today, Matthew Taylor from Barclays maintained a Buy rating on NuVasive (NASDAQ: NUVA), with a price target of $62. The company’s shares opened today at $48.39, close to its 52-week low of $44.62.

According to TipRanks.com, Taylor is a 4-star analyst with an average return of 7.0% and a 62.8% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on NuVasive is Strong Buy and the average price target is $66.44, representing a 37.3% upside.

In a report issued on February 13, BTIG also assigned a Buy rating to the stock with a $74 price target.

NuVasive’s market cap is currently $2.46B and has a P/E ratio of 40.53. The company has a book value ratio of 3.2519.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V.